Citigroup Inc Larimar Therapeutics, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 30,356 shares of LRMR stock, worth $109,888. This represents 0.0% of its overall portfolio holdings.

Number of Shares

30,356

Previous 9,160 231.4%

Holding current value

$109,888

Previous $66,000 200.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$6.3 - $10.68 $133,534 - $226,373	21,196 Added 231.4%	30,356 $198,000
Q2 2024 Aug 12, 2024	BUY	$6.33 - $9.89 $27,067 - $42,289	4,276 Added 87.55%	9,160 $66,000
Q1 2024 May 10, 2024	BUY	$4.2 - $13.28 $5,124 - $16,201	1,220 Added 33.3%	4,884 $37,000
Q4 2023 Feb 09, 2024	BUY	$2.35 - $4.71 $8,565 - $17,167	3,645 Added 19184.21%	3,664 $16,000
Q3 2023 Nov 09, 2023	SELL	$3.08 - $4.49 $23,774 - $34,658	-7,719 Reduced 99.75%	19 $0
Q2 2023 Aug 10, 2023	SELL	$3.13 - $5.27 $96,238 - $162,036	-30,747 Reduced 79.89%	7,738 $24,000
Q1 2023 May 11, 2023	BUY	$4.0 - $6.68 $153,940 - $257,079	38,485 New	38,485 $174,000
Q3 2022 Nov 10, 2022	SELL	$1.53 - $3.64 $90 - $214	-59 Reduced 21.45%	216 $1,000
Q2 2022 Aug 10, 2022	SELL	$1.9 - $3.98 $210 - $441	-111 Reduced 28.76%	275 $1,000
Q1 2022 May 12, 2022	SELL	$3.65 - $10.84 $576 - $1,712	-158 Reduced 29.04%	386 $2,000
Q4 2021 Feb 10, 2022	SELL	$8.86 - $13.47 $117,386 - $178,464	-13,249 Reduced 96.06%	544 $6,000
Q3 2021 Nov 10, 2021	BUY	$9.61 - $15.11 $132,550 - $208,412	13,793 New	13,793 $159,000

Others Institutions Holding LRMR

# of Institutions

127

Shares Held

67.3M

Call Options Held

280K

Put Options Held

76.3K

View Full List

About Larimar Therapeutics, Inc.

Ticker LRMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,269,200
Market Cap $157M
Description
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...

More about LRMR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account